BSC® Solutions
VOICES
Explore our FDA-focused solution areas to see how we support medical device and pharmaceutical companies across regulatory pathways and product types, from early strategy through approval-ready submissions.
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 204 54" xmlns="http://www.w3.org/2000/svg"><g d="M 184.738 48 C 174.462 48 169.702 40.916 169.702 27.168 C 169.702 12.972 174.77 6 185.242 6 C 193.39 6 197.87 10.2 198.934 19.16 L 191.85 20.112 C 191.43 14.792 189.106 12.636 185.13 12.636 C 178.466 12.636 176.926 18.656 176.926 26.72 C 176.926 37.136 179.502 41.364 185.018 41.364 C 189.106 41.364 191.514 39.04 192.046 33.076 L 199.102 33.944 C 198.066 43.296 193.11 48 184.738 48 Z M 155.083 48 C 147.187 48 141.699 43.576 141.223 34.504 L 148.363 33.692 C 148.671 39.404 151.135 41.728 155.139 41.728 C 158.527 41.728 160.627 40.048 160.627 36.828 C 160.627 32.432 156.819 31.088 152.619 29.66 C 147.355 27.868 141.391 25.852 141.391 17.536 C 141.391 9.752 146.599 6 154.355 6 C 162.419 6 166.899 10.004 167.431 18.6 L 160.319 19.384 C 160.067 14.316 158.107 12.272 154.131 12.272 C 150.827 12.272 148.615 13.728 148.615 17.032 C 148.615 21.344 152.339 22.632 156.147 23.92 C 162.027 25.908 167.795 27.812 167.795 36.044 C 167.795 43.632 162.923 48 155.083 48 Z M 113.5 47.075 L 113.5 6.923 L 127.864 6.923 C 134.864 6.923 138.476 10.563 138.476 16.947 C 138.476 21.063 136.992 24.311 133.772 25.935 C 137.44 27.195 139.148 30.471 139.148 35.231 C 139.148 42.455 135.228 47.075 128.396 47.075 Z M 120.612 40.439 L 127.248 40.439 C 130.216 40.439 131.952 38.479 131.952 34.615 C 131.952 31.031 130.356 28.903 127.332 28.903 L 120.612 28.903 Z M 120.612 23.499 L 126.884 23.499 C 129.712 23.499 131.308 21.483 131.308 18.235 C 131.308 14.651 129.348 13.559 126.996 13.559 L 120.612 13.559 Z M 93.788 45.234 L 103.096 45.234 C 82.677 45.234 79.944 9 64.86 9 C 49.776 9 47.144 45.234 24.422 45.234 L 0 45.234 M 0.5 45.142 C 35.832 45.142 29.292 0 47.142 0 C 64.992 0 60.655 45.142 94.286 45.142" fill="transparent" height="48px" id="iFqsXxQ2X" transform="translate(2 3)" width="199.10199966430665px"><path d="M 71.238 42 C 60.962 42 56.202 34.916 56.202 21.168 C 56.202 6.972 61.27 0 71.742 0 C 79.89 0 84.37 4.2 85.434 13.16 L 78.35 14.112 C 77.93 8.792 75.606 6.636 71.63 6.636 C 64.966 6.636 63.426 12.656 63.426 20.72 C 63.426 31.136 66.002 35.364 71.518 35.364 C 75.606 35.364 78.014 33.04 78.546 27.076 L 85.602 27.944 C 84.566 37.296 79.61 42 71.238 42 Z M 41.583 42 C 33.687 42 28.199 37.576 27.723 28.504 L 34.863 27.692 C 35.171 33.404 37.635 35.728 41.639 35.728 C 45.027 35.728 47.127 34.048 47.127 30.828 C 47.127 26.432 43.319 25.088 39.119 23.66 C 33.855 21.868 27.891 19.852 27.891 11.536 C 27.891 3.752 33.099 0 40.855 0 C 48.919 0 53.399 4.004 53.931 12.6 L 46.819 13.384 C 46.567 8.316 44.607 6.272 40.631 6.272 C 37.327 6.272 35.115 7.728 35.115 11.032 C 35.115 15.344 38.839 16.632 42.647 17.92 C 48.527 19.908 54.295 21.812 54.295 30.044 C 54.295 37.632 49.423 42 41.583 42 Z M 0 41.075 L 0 0.923 L 14.364 0.923 C 21.364 0.923 24.976 4.563 24.976 10.947 C 24.976 15.063 23.492 18.311 20.272 19.935 C 23.94 21.195 25.648 24.471 25.648 29.231 C 25.648 36.455 21.728 41.075 14.896 41.075 Z M 7.112 34.439 L 13.748 34.439 C 16.716 34.439 18.452 32.479 18.452 28.615 C 18.452 25.031 16.856 22.903 13.832 22.903 L 7.112 22.903 Z M 7.112 17.499 L 13.384 17.499 C 16.212 17.499 17.808 15.483 17.808 12.235 C 17.808 8.651 15.848 7.559 13.496 7.559 L 7.112 7.559 Z" fill="rgb(0, 0, 0)" height="42px" id="TmpG5bKj6" transform="translate(113.5 6)" width="85.60199966430665px"/><path d="M 93.788 36.234 L 103.096 36.234 C 82.677 36.234 79.944 0 64.86 0 C 49.776 0 47.144 36.234 24.422 36.234 L 0 36.234" fill="transparent" height="36.23400000000001px" id="hDuxK1Epu" stroke-dasharray="" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="3.861" stroke="rgb(0, 0, 0)" transform="translate(0 9)" width="103.096px"/><path d="M 0 45.142 C 35.332 45.142 28.792 0 46.642 0 C 64.492 0 60.155 45.142 93.786 45.142" fill="transparent" height="45.141999999999996px" id="l4coILr9Z" stroke-dasharray="" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="3.861" stroke="rgb(0, 0, 0)" transform="translate(0.5 0)" width="93.786px"/></g></svg>)
All
Knowledge Base
News
Glossary
Questions & Answers
510(k)
Advisory Committee (Panel Meeting)
Annotated CRF
Approvable Letter
Audit Trail
Bayesian Methods
Benefit-Risk Assessment
Blinded Assessment
Blinding/Masking
Breakthrough Device Designation
Clinical Data Interchange Standards Consortium
Clinical Events Committee
Clinical Study Report
Co-Primary Endpoints
Competing Risks Analysis
Complete Response Letter
Composite Endpoint
Conditional Power
Confidence Interval
Core Lab
Crossover Design
Data Safety Monitoring Board/Data Monitoring Committee
Data Specifications
Database Lock
De Novo
Define.xml
Device Deficiency
Effect Size
Efficacy Endpoints
Electronic Case Report Form
Electronic Common Technical Document
Electronic Data Capture
Enrollment/Accrual
Equivalence Design
Exploratory Endpoint
Hierarchical (Mixed-Effects) Model
Historical Controls
Humanitarian Device Exemption
Informative Prior
Informed Consent Form
Institutional Review Board/Ethics Committee
Integrated Summary of Effectiveness
Integrated Summary of Safety
Intercurrent Event
Investigational Device Exemption
Investigator's Brochure
Lost to Follow-up
Major Adverse Cardiac Events
Medical Dictionary for Regulatory Activities
Meta-Analysis
Methodological Innovation
Minimum Clinically Important Difference
Multiple Imputation
Neck Disability Index
Non-Inferiority Design
Non-Informative (Vague) Prior
Null Hypothesis
Observer-Reported Outcomes (ObsROs)
p-value
Panel Preparation
Pattern-Mixture Models
Performance Goal (Objective Performance Criterion)
Pivotal Trial
Platform Trial
Post-Market Study
Posterior (Posterior Distribution)
Posterior Probability of Success
Pre-Sub Package
Premarket Approval
Primary Endpoint
Principal Stratification
Prior (Prior Distribution)
Propensity Score Methods
Protocol
Protocol Amendment
Protocol Deviation
Radiographic Success
Random Effects
Randomized Controlled Trial
Real World Data
Real World Evidence
Registry Trial
Regulatory Biostatistics
Rescue Therapy
Response-Adaptive Randomization
Sample Size
Seamless Phase II/III Design
Secondary Endpoint
Sensitivity Analysis
Sham Control
Single-Arm Study
Standard Operating Procedures
Statistical Analysis Plan
Statistical Power
Steering Committee
Stopping Rules
Summary of Safety and Effectiveness Data
Superiority Design
Surrogate Endpoint
Synthetic Control Arm
Tables, Listings, and Figures
Type I Error (Alpha)
Type II Error (Beta)
Validated Environment
Validation
Version Control
WOMAC
Adaptive Design
Adaptive Enrichment Design
Alpha-Spending Function
Interim Analysis
Sample Size Re-estimation
Weakly Informative Prior
ADaM (Analysis Data Model)
Study Data Tabulation Model
First-in-Human Study
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
Center for Drug Evaluation and Research (CDER)
FDA Guidance Document
FDA Pre-Submission
Type A Meeting
Type B Meeting
Type C Meeting
ICH E3
ICH E6
ICH E9
ICH E9(R1)
International Council for Harmonisation
CE Marking
European Medicines Agency
Health Canada
National Health Commission of the People’s Republic of China
National Medical Products Administration
Notified Body
Pharmaceuticals and Medical Devices Agency
Last Observation Carried Forward
Missing at Random
Missing Completely at Random (MCAR)
Missing Data
Missing Not at Random
Tipping Point Analysis
Oswestry Disability Index
Patient-Reported Outcomes
SF-36
Visual Analog Scale
21 CFR Part 11
Good Clinical Practice
Good Laboratory Practice
Good Manufacturing Practice
Adverse Event
Preferred Term
Safety Endpoints
Serious Adverse Event
System Organ Class
Unanticipated Adverse Device Effect
SAS
Frequentist Methods
Full Analysis Set
Intent-to-Treat Analysis Set
Modified Intent-to-Treat Analysis Set
Per-Protocol Analysis Set
Futility Analysis
Parallel Design
Follow-up
Feasibility Study
All
Knowledge Base
News
Glossary
Questions & Answers
510(k)
Advisory Committee (Panel Meeting)
Annotated CRF
Approvable Letter
Audit Trail
Bayesian Methods
Benefit-Risk Assessment
Blinded Assessment
Blinding/Masking
Breakthrough Device Designation
Clinical Data Interchange Standards Consortium
Clinical Events Committee
Clinical Study Report
Co-Primary Endpoints
Competing Risks Analysis
Complete Response Letter
Composite Endpoint
Conditional Power
Confidence Interval
Core Lab
Crossover Design
Data Safety Monitoring Board/Data Monitoring Committee
Data Specifications
Database Lock
De Novo
Define.xml
Device Deficiency
Effect Size
Efficacy Endpoints
Electronic Case Report Form
Electronic Common Technical Document
Electronic Data Capture
Enrollment/Accrual
Equivalence Design
Exploratory Endpoint
Hierarchical (Mixed-Effects) Model
Historical Controls
Humanitarian Device Exemption
Informative Prior
Informed Consent Form
Institutional Review Board/Ethics Committee
Integrated Summary of Effectiveness
Integrated Summary of Safety
Intercurrent Event
Investigational Device Exemption
Investigator's Brochure
Lost to Follow-up
Major Adverse Cardiac Events
Medical Dictionary for Regulatory Activities
Meta-Analysis
Methodological Innovation
Minimum Clinically Important Difference
Multiple Imputation
Neck Disability Index
Non-Inferiority Design
Non-Informative (Vague) Prior
Null Hypothesis
Observer-Reported Outcomes (ObsROs)
p-value
Panel Preparation
Pattern-Mixture Models
Performance Goal (Objective Performance Criterion)
Pivotal Trial
Platform Trial
Post-Market Study
Posterior (Posterior Distribution)
Posterior Probability of Success
Pre-Sub Package
Premarket Approval
Primary Endpoint
Principal Stratification
Prior (Prior Distribution)
Propensity Score Methods
Protocol
Protocol Amendment
Protocol Deviation
Radiographic Success
Random Effects
Randomized Controlled Trial
Real World Data
Real World Evidence
Registry Trial
Regulatory Biostatistics
Rescue Therapy
Response-Adaptive Randomization
Sample Size
Seamless Phase II/III Design
Secondary Endpoint
Sensitivity Analysis
Sham Control
Single-Arm Study
Standard Operating Procedures
Statistical Analysis Plan
Statistical Power
Steering Committee
Stopping Rules
Summary of Safety and Effectiveness Data
Superiority Design
Surrogate Endpoint
Synthetic Control Arm
Tables, Listings, and Figures
Type I Error (Alpha)
Type II Error (Beta)
Validated Environment
Validation
Version Control
WOMAC
Adaptive Design
Adaptive Enrichment Design
Alpha-Spending Function
Interim Analysis
Sample Size Re-estimation
Weakly Informative Prior
ADaM (Analysis Data Model)
Study Data Tabulation Model
First-in-Human Study
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
Center for Drug Evaluation and Research (CDER)
FDA Guidance Document
FDA Pre-Submission
Type A Meeting
Type B Meeting
Type C Meeting
ICH E3
ICH E6
ICH E9
ICH E9(R1)
International Council for Harmonisation
CE Marking
European Medicines Agency
Health Canada
National Health Commission of the People’s Republic of China
National Medical Products Administration
Notified Body
Pharmaceuticals and Medical Devices Agency
Last Observation Carried Forward
Missing at Random
Missing Completely at Random (MCAR)
Missing Data
Missing Not at Random
Tipping Point Analysis
Oswestry Disability Index
Patient-Reported Outcomes
SF-36
Visual Analog Scale
21 CFR Part 11
Good Clinical Practice
Good Laboratory Practice
Good Manufacturing Practice
Adverse Event
Preferred Term
Safety Endpoints
Serious Adverse Event
System Organ Class
Unanticipated Adverse Device Effect
SAS
Frequentist Methods
Full Analysis Set
Intent-to-Treat Analysis Set
Modified Intent-to-Treat Analysis Set
Per-Protocol Analysis Set
Futility Analysis
Parallel Design
Follow-up
Feasibility Study
All
Knowledge Base
News
Whitepapers
Therapy Areas
Service Offerings
Glossary
Questions & Answers
510(k)
Advisory Committee (Panel Meeting)
Annotated CRF
Approvable Letter
Audit Trail
Bayesian Methods
Benefit-Risk Assessment
Blinded Assessment
Blinding/Masking
Breakthrough Device Designation
Clinical Data Interchange Standards Consortium
Clinical Events Committee
Clinical Study Report
Co-Primary Endpoints
Competing Risks Analysis
Complete Response Letter
Composite Endpoint
Conditional Power
Confidence Interval
Core Lab
Crossover Design
Data Safety Monitoring Board/Data Monitoring Committee
Data Specifications
Database Lock
De Novo
Define.xml
Device Deficiency
Effect Size
Efficacy Endpoints
Electronic Case Report Form
Electronic Common Technical Document
Electronic Data Capture
Enrollment/Accrual
Equivalence Design
Exploratory Endpoint
Hierarchical (Mixed-Effects) Model
Historical Controls
Humanitarian Device Exemption
Informative Prior
Informed Consent Form
Institutional Review Board/Ethics Committee
Integrated Summary of Effectiveness
Integrated Summary of Safety
Intercurrent Event
Investigational Device Exemption
Investigator's Brochure
Lost to Follow-up
Major Adverse Cardiac Events
Medical Dictionary for Regulatory Activities
Meta-Analysis
Methodological Innovation
Minimum Clinically Important Difference
Multiple Imputation
Neck Disability Index
Non-Inferiority Design
Non-Informative (Vague) Prior
Null Hypothesis
Observer-Reported Outcomes (ObsROs)
p-value
Panel Preparation
Pattern-Mixture Models
Performance Goal (Objective Performance Criterion)
Pivotal Trial
Platform Trial
Post-Market Study
Posterior (Posterior Distribution)
Posterior Probability of Success
Pre-Sub Package
Premarket Approval
Primary Endpoint
Principal Stratification
Prior (Prior Distribution)
Propensity Score Methods
Protocol
Protocol Amendment
Protocol Deviation
Radiographic Success
Random Effects
Randomized Controlled Trial
Real World Data
Real World Evidence
Registry Trial
Regulatory Biostatistics
Rescue Therapy
Response-Adaptive Randomization
Sample Size
Seamless Phase II/III Design
Secondary Endpoint
Sensitivity Analysis
Sham Control
Single-Arm Study
Standard Operating Procedures
Statistical Analysis Plan
Statistical Power
Steering Committee
Stopping Rules
Summary of Safety and Effectiveness Data
Superiority Design
Surrogate Endpoint
Synthetic Control Arm
Tables, Listings, and Figures
Type I Error (Alpha)
Type II Error (Beta)
Validated Environment
Validation
Version Control
WOMAC
Adaptive Design
Adaptive Enrichment Design
Alpha-Spending Function
Interim Analysis
Sample Size Re-estimation
Weakly Informative Prior
ADaM (Analysis Data Model)
Study Data Tabulation Model
First-in-Human Study
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiological Health (CDRH)
Center for Drug Evaluation and Research (CDER)
FDA Guidance Document
FDA Pre-Submission
Type A Meeting
Type B Meeting
Type C Meeting
ICH E3
ICH E6
ICH E9
ICH E9(R1)
International Council for Harmonisation
CE Marking
European Medicines Agency
Health Canada
National Health Commission of the People’s Republic of China
National Medical Products Administration
Notified Body
Pharmaceuticals and Medical Devices Agency
Last Observation Carried Forward
Missing at Random
Missing Completely at Random (MCAR)
Missing Data
Missing Not at Random
Tipping Point Analysis
Oswestry Disability Index
Patient-Reported Outcomes
SF-36
Visual Analog Scale
21 CFR Part 11
Good Clinical Practice
Good Laboratory Practice
Good Manufacturing Practice
Adverse Event
Preferred Term
Safety Endpoints
Serious Adverse Event
System Organ Class
Unanticipated Adverse Device Effect
SAS
Frequentist Methods
Full Analysis Set
Intent-to-Treat Analysis Set
Modified Intent-to-Treat Analysis Set
Per-Protocol Analysis Set
Futility Analysis
Parallel Design
Follow-up
Feasibility Study
Featured Resources
Four ways customers lead the change
Four ways customers lead the change
with measurable success.
with measurable success.
Subscribe updates
Get regulatory insights
that help you work smarter.
Receive updates on clinical trial methodology, regulatory developments, FDA guidance, and practical biostatistical insights drawn from real-world experience.
Subscribe updates
Get regulatory insights
that help you work smarter.
Receive updates on clinical trial methodology, regulatory developments, FDA guidance, and practical biostatistical insights drawn from real-world experience.
Subscribe updates
Get regulatory insights
that help you work smarter.
Receive updates on clinical trial methodology, regulatory developments, FDA guidance, and practical biostatistical insights drawn from real-world experience.
Subscribe updates
Get regulatory insights
that help you work smarter.
Receive updates on clinical trial methodology, regulatory developments, FDA guidance, and practical biostatistical insights drawn from real-world experience.
Testimonials
See what our sponsors say about BSC
On Experience
Battle ground tested. There is nothing that David and team haven't seen over the years – good bad and ugly.
• VP, Clinical Operations
• CEO, Medical Device Company
• Former FDA Regulator
Let's help you find a path
to get your idea into the market
About & Services
Working With BSC
Trial Design & Methodology
Regulatory & FDA
Analysis & Programming
Cost & Contracting
Expertise & Qualifications
Practical Considerations
Common Concerns
What does BSC specialize in?
What types of clients do you work with?
What therapeutic areas do you cover?
How is BSC different from a CRO?
What size projects do you handle?
Let's help you find a path
to get your idea into the market
About & Services
Working With BSC
Trial Design & Methodology
Regulatory & FDA
Analysis & Programming
Cost & Contracting
Expertise & Qualifications
Practical Considerations
Common Concerns
What does BSC specialize in?
What types of clients do you work with?
What therapeutic areas do you cover?
How is BSC different from a CRO?
What size projects do you handle?
Let's help you find a path
to get your idea into the market
About & Services
Working With BSC
Trial Design & Methodology
Regulatory & FDA
Analysis & Programming
Cost & Contracting
Expertise & Qualifications
Practical Considerations
Common Concerns
What does BSC specialize in?
What types of clients do you work with?
What therapeutic areas do you cover?
How is BSC different from a CRO?
What size projects do you handle?
Let's help you find a path
to get your idea into the market
About & Services
Working With BSC
Trial Design & Methodology
Regulatory & FDA
Analysis & Programming
Cost & Contracting
Expertise & Qualifications
Practical Considerations
Common Concerns
What does BSC specialize in?
What types of clients do you work with?
What therapeutic areas do you cover?
How is BSC different from a CRO?
What size projects do you handle?
Featured Resources
Get regulatory insights
from BSC®
Featured Resources
Get regulatory insights
from BSC®
Featured Resources
Get regulatory insights
from BSC®
Featured Resources
Get regulatory insights
from BSC®
Partner with us
Partner with us
Partner with us
Request Expert Review
Backed by Regulatory Experience.
Engage directly with senior biostatisticians to review your clinical strategy, statistical approach, or FDA submission — with clarity, rigor, and regulatory perspective.
Confidential discussion with senior biostatisticians experienced in FDA submissions.
Request Expert Review
Backed by Regulatory Experience.
Engage directly with senior biostatisticians to review your clinical strategy, statistical approach, or FDA submission — with clarity, rigor, and regulatory perspective.
Confidential discussion with senior biostatisticians experienced in FDA submissions.
Request Expert Review
Backed by Regulatory Experience.
Engage directly with senior biostatisticians to review your clinical strategy, statistical approach, or FDA submission — with clarity, rigor, and regulatory perspective.
Confidential discussion with senior biostatisticians experienced in FDA submissions.
Request Expert Review
Backed by Regulatory Experience.
Engage directly with senior biostatisticians to review your clinical strategy, statistical approach, or FDA submission — with clarity, rigor, and regulatory perspective.
Confidential discussion with senior biostatisticians experienced in FDA submissions.
Use your preferred LLM to explore BSC®
Use your preferred LLM to explore BSC®